All News

Raynaud-hand2.jpg

Raynaud and Microvascular Complications with New Migraine Meds

d Jack Cush, MD

A new study of calcitonin gene-related peptide (CGRP) antagonists for migraine headaches found that a small subset manifested Raynaud phenomenon and other had microvascular complications, suggesting that CGRP antagonists should be used in caution in patients with Raynauds. 

Read Article
Christian, charles, leader, rheum

Dr. Charles Christian of HSS Honored

d Jack Cush, MD

In the current issue of Annals of Rheumatic Disease, Dr. Peggy Crow honors the life and career of one the great, historic rheumatologists of all time: Dr. Charles Christian. For those interested in the history of rheumatology, mentoring and leadership, this is a good read. For those interested in leading a truly good life, and being a real role model, this is a must read.

Read Article
back, LBP, spine, AS

Broadalumab Efficacy in Axial Spondyloarthritis

d Jack Cush, MD

Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).

Read Article
Tonight! Join us for Tuesday Night Rheumatology with Dr. Philip Robinson and Dr. Iain McInness. We'll discuss highlight sessions for RheumNow Live 2021 #RNL2021 https://t.co/oJ4xYKLrj4 https://t.co/K1OQz40aZ1

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Planes, Trains and COVID Distancing MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy). https://t.co/tGs9GopeGu https://t.co/ZRMltTpYgW

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Broadalumab Efficacy in Axial Spondyloarthritis Broadalumab, an anti-interleukin-17 receptor A monoclonal antibody, is FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axSpA. https://t.co/V0zKbFMgy7 https://t.co/U5CGXUF7Sw

Links:

Dr. John Cush RheumNow ( View Tweet)
Dual seropositivity with RF/ACPA autoantibody higher titers were strongly associated with prevalent RA-ILD (OR 2.90; developed in 3.7%). ILD more likely with high titer RF (HR 3.4) than high titer CCP (HR 1.9). https://t.co/ebvJjatQSw

Links:

Dr. John Cush RheumNow ( View Tweet)

304 pts w/ Knee OA studied by MRI and atorvastatin 40 mg qd was no better than placebo in reducing cartilage volume loss, BM lesions, pain, or function over 2 years https://t.co/MIdIFQ9qzs

Links:

Dr. John Cush RheumNow ( View Tweet)

Serious problem! Pulmonologists uniformly believe that MTX causes and/or worsens ILD. MTX causes hypersensitivity pneumonitis, not ILD. RA, lupus DM, PSS cause ILD and they may need MTX to manage their disease. Do your own research, look at this paper to start. https://t.co/DHC5ikhCf6

Links:

Dr. John Cush RheumNow ( View Tweet)

There's a special, deep hell for insurers/PBM's that give patients a hassle over paying for a cheap drug like methotrexate. And these days it's looking like it's going to be very, very crowded.

Ethan Craig rheumecraig ( View Tweet)

Another @preventiveneur1 paper just published. @tomrptaylor looked at demyelinating events reported in people taking anti-TNF in the BSRBR. We found that these events are uncommon in people with underlying rheumatological disease https://t.co/qCaF6YMLAh

Links:

Ruth Dobson drruthdobson ( View Tweet)

#RNL2021 coverage from @doctorRBC "Biosimilars are on their way. Coming to you in 2024! They will most likely be cheaper for insurance companies, but will they be cheaper for patients? " #RheumNow

Dr. John Cush RheumNow ( View Tweet)

Join us for Tuesday Night Rheumatology with Dr. Philip Robinson and Dr. Iain McInness. We'll discuss highlight sessions for RheumNow Live 2021 #RNL2021 https://t.co/oJ4xYL32aC https://t.co/Eix01GlWoj

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: New, Improved Therapy for Pompe Disease https://t.co/dEZ9Y0biHu https://t.co/rXh7fH13rc

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. R Fleischmann "Don't be afraid to use TOFA!" FDA warnings on⬆️ MACE/malign based on 1 study (Pfizer 1133) in high risk patients. Older age, tobacco use are risks for MACE/CV events and cancer. Meta-analyses, registries, clinical trials program do NOT show⬆️ risk #RNL2021 https://t.co/4p9YqyDrGz
k dao KDAO2011 ( View Tweet)
Randomized trial of 206 adults with knee OA found that a web-based exercise intervention supported by text messaging improved knee pain and function at 24 weeks vs web-based information alone. (MCID pain 72.1% vs 42%) https://t.co/h5UaedS4Zm

Links:

Dr. John Cush RheumNow ( View Tweet)

Not in the US, but biosimilar infliximab (CT-P13) is being used subcutaneously in the EU and Canada. Analysis of 2 RCTs shows (compared to IV inflectra or remicade) SC CT-P13 greater DAS28-CRP, CDAI and SDAI response rates. https://t.co/prSVJ0BIdd

Links:

Dr. John Cush RheumNow ( View Tweet)

Have you had the chance to listen to the latest RheumNow podcast on combination biologics? https://t.co/FFtYHhw7Qc https://t.co/YT1h8iL647

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Planes, Trains and COVID Distancing MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy). https://t.co/tGs9Go7DhU https://t.co/Gz9L1ERcUU

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Autoimmune Risk of Death Up during COVID A population-based study in the UK shows patients with RAIRD were 44% more likely to die during the '20 COVID-19 pandemic (Mar - Apr) compared to either the general population or their pre-COVID risk. https://t.co/e1vWOjGglt https://t.co/OIaM3Hx7BO

Links:

Dr. John Cush RheumNow ( View Tweet)
×